205 related articles for article (PubMed ID: 35895109)
1. A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment.
Kuo CL; Chou HY; Lien HW; Yeh CA; Wang JR; Chen CH; Fan CC; Hsu CP; Kao TY; Ko TM; Lee AY
Cancer Immunol Immunother; 2023 Feb; 72(2):351-369. PubMed ID: 35895109
[TBL] [Abstract][Full Text] [Related]
2. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
3. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
4. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
5. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
7. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response.
Currenti J; Mishra A; Wallace M; George J; Sharma A
Biochem Soc Trans; 2023 Apr; 51(2):597-612. PubMed ID: 36938978
[TBL] [Abstract][Full Text] [Related]
9. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
[TBL] [Abstract][Full Text] [Related]
10. An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies.
Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
[TBL] [Abstract][Full Text] [Related]
11. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
12. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
[TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Schmolze D; Su C; Zain J; Moyal L; Hodak E; Sanchez JF; Lee PP; Feng M; Rosen ST; Querfeld C
JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427589
[TBL] [Abstract][Full Text] [Related]
15. CXCL8 induces M2 macrophage polarization and inhibits CD8
Shao Y; Lan Y; Chai X; Gao S; Zheng J; Huang R; Shi Y; Xiang Y; Guo H; Xi Y; Yang L; Yang T
FASEB J; 2023 Oct; 37(10):e23173. PubMed ID: 37665572
[TBL] [Abstract][Full Text] [Related]
16. PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis.
Go EJ; Yang H; Lee SJ; Yang HG; Shin JA; Lee WS; Lim HS; Chon HJ; Kim C
Oncoimmunology; 2023; 12(1):2259212. PubMed ID: 37744990
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Mukherjee D; Romano E; Walshaw R; Zeef LAH; Banyard A; Kitcatt SJ; Cheadle EJ; Tuomela K; Pendharkar S; Al-Deka A; Salerno B; Raby S; Mills IG; Honeychurch J; Illidge TM
Oncoimmunology; 2023; 12(1):2223094. PubMed ID: 37332616
[TBL] [Abstract][Full Text] [Related]
18. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
19. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials.
Li L; Wen Q; Ding R
Front Oncol; 2022; 12():905520. PubMed ID: 35957885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]